[1]曲慧.静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效及安全性研究[J].中国计划生育和妇产科,2018,(11):28-31.
　QU Hui.Efficacy and safety of intravenous tropisetron hydrochloride combined with thalidomide in the treatment of nausea and vomiting induced by chemotherapy in ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(11):28-31.
点击复制

静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效及安全性研究
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年11期
页码:
28-31
栏目:
论著与临床
出版日期:
2018-11-25

文章信息/Info

Title:
Efficacy and safety of intravenous tropisetron hydrochloride combined with thalidomide in the treatment of nausea and vomiting induced by chemotherapy in ovarian cancer
作者:
曲慧
中国医科大学附属盛京医院妇产科
Author(s):
QU Hui
Department of Gynaecology and Obstetrics, Shengjing Hospital Affiliated to China Medical University, Shenyang Liaoning 110000,P.R.China
关键词:
卵巢癌; 化疗; 恶心呕吐; 盐酸托烷司琼; 沙利度胺
Keywords:
ovarian cancer;  chemotherapy;  nausea and vomiting;  tropisetron hydrochloride;  thalidomide
分类号:
R 737.31
摘要:
目的 探讨静脉用盐酸托烷司琼及联合沙利度胺治疗卵巢癌化疗所致恶心呕吐的疗效及安全性。方法回顾性分析2015年1月至2017年7月中国医科大学附属盛京医院收治的94例卵巢癌患者，根据治疗方法将其分为两组，各47例。两组均采用紫杉醇联合卡铂（TC）方案化疗，对照组使用盐酸托烷司琼静脉滴注治疗，研究组在对照组的基础上加用沙利度胺口服治疗。分别评价两组急性期和延迟期止恶心、止呕吐的疗效，统计两组欧洲肿瘤研究与治疗中心生存质量核心问卷评分，比较两组不良反应情况。结果研究组急性期和延迟期止恶心、止呕吐总有效率高于对照组（P＜005）；两组化疗后15 d欧洲肿瘤研究与治疗中心生存质量核心问卷评分均升高（P＜005），且研究组高于对照组（P＜005）；两组不良反应发生率比较差异无统计学意义（P＞005）。结论与静脉用盐酸托烷司琼相比，盐酸托烷司琼联合口服沙利度胺治疗卵巢癌化疗所致恶心呕吐疗效更好，且安全性高。
Abstract:
ObjectiveTo compare and analyze the efficacy and safety of tropisetron hydrochloride injection and thalidomide in the treatment of nausea and vomit induced by chemotherapy of ovarian cancer. MethodsA retrospective analysis of 94 patients with ovarian cancer admitted to Shengjing Hospital Affiliated to China Medical University from January 2015 to July 2017 was divided into two groups according to the treatment methods, with 47 cases in each group.Both groups were treated with paclitaxel plus carboplatin (TC) regimen, and the control group was treated with intravenous infusion of tropisetron hydrochloride. The efficacies on stopping nausea and vomit in acute and delayed periods of two groups were evaluated respectively, the Europe Organization for Research And Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C 30) scores of the two groups were statistically analyzed, and the adverse reactions in the two groups were compared. ResultsThe total effective rates of stopping nausea in acute and delayed periods of the study group were significantly higher than those of the control group (P<005); the total effective rates of stopping vomit in the acute and delayed periods of the study group were significantly higher than those of the control group (P<005); the EORTC QLQ-C30 scores at 15d after chemotherapy in the two groups were significantly increased (P<005), and the study group was significantly higher than the control group (P<005); there was no significant difference in the incidence of adverse reactions between the study group and the control group (P>005). ConclusionCompared with intravenous tropisetron hydrochloride, tropisetron hydrochloride combined with oral thalidomide is more effective and safer in the treatment of nausea and vomiting caused by chemotherapy in ovarian cancer.

参考文献/References:

［1］王清，孙柳，王艳玲，等．1992年～2014年我国卵巢癌患者生活质量相关文献计量分析　［J］．现代临床护理，2016，15 （4）：47-50． ［2］杨柳，黄爽．卵巢癌治疗方法的研究进展 ［J］．中国医药导报，2015，12 （11）：38-41． ［3］MYSTAKIDOU K, BEFON S, LIOSSI C, et al. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer ［J］. Cancer, 1998, 83 (6): 1214-1223. ［4］张静，康红刚，王宝中，等．帕洛诺司琼联合沙利度胺预防肺癌化疗引起恶心呕吐的临床观察　［J］．中国肿瘤临床与康复，2016，23 （8）：943-946． ［5］全国肿瘤防治研究办公室，中国抗癌协会. 中国常见恶性肿瘤诊治规范 ［Ｍ］．北京: 北京医科大学、中国协和医科大学联合出版社，1990: 26-27. ［6］孙燕.内科肿瘤学 ［M］.北京:人民卫生出版社，2001：435-436． ［7］MONTAZERI A, HARIRCHI I, VAHDANI M, et al. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): translation and validation study of the iranian version ［J］. Supportive Care in Cancer, 1999, 7 (6): 400-406. ［8］张爽爽，夏庆民，郑荣寿，等．中国2010年卵巢癌发病与死亡分析 ［J］．中国肿瘤，2016，25 （3）：169-173． ［9］MAZOUNI C, NAVEAU A, KANE Aminata, et al. The role of oncoplastic breast surgery in the management of breast cancer treated with primary chemotherapy ［J］. Breast (Edinburgh, Scotland), 2013, 22 (6): 1189-1193. ［10］范淑英，王健，刘芸，等．紫杉醇联合卡铂周疗和三周疗法治疗卵巢癌的Meta分析 ［J］．解放军医学杂志，2016，41 （7）：589-597． ［11］李海蓉，董利红．抗肿瘤药致不良反应473例分析 ［J］．中国药房，2014，25 （10）：926-928． ［12］SORBE B G, BERGLIND A M, ANDERSSON H, et al. A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis ［J］. Cancer, 1998, 83 (5): 1022-1032. ［13］柴琴．帕洛诺司琼和托烷司琼预防化疗药物所致恶心呕吐临床疗效观察 ［J］．临床肺科杂志，2015，20 （6）：1004-1006． ［14］侯敏，赵妍丽，李秋梅，等．托烷司琼与格拉司琼联合甲氧氯普胺预防化疗所致恶心、呕吐的成本-效益分析 ［J］．川北医学院学报，2014，29 （2）：177-180． ［15］孙媛媛，谢军，鲍健，等．托烷司琼联合地塞米松预防顺铂化疗所致恶心呕吐的临床研究 ［J］．安徽医学，2014，35 （3）：282-284． ［16］BAROSI G, GROSSI A, COMOTTI B, et al. Safety and efficacy of Thalidomide in patients with myelofibrosis with myeloid metaplasia ［J］. British Journal of Haematology, 2001, 114 (1): 78-83. ［17］杜娟．沙利度胺对卵巢癌的化疗前景 ［J］．现代肿瘤医学，2013，21 （12）：2850-2853． ［18］彭晔，张旭刚，谢娜，等．沙利度胺联合紫杉醇+顺铂方案治疗老年晚期非小细胞肺癌的疗效观察 ［J］．疑难病杂志，2014，13（1）：49-52． ［19］陈奕霖，罗德红，王美江．沙利度胺用于预防化疗病人恶心、呕吐的临床疗效观察 ［J］．现代预防医学，2013，40 （2）：382-383． ［20］李敏，高尔云，崔方博，等．沙利度胺联合昂丹司琼预防肺癌化疗所致恶心呕吐的临床研究 ［J］．现代肿瘤医学，2016，24（17）：2719-2723．

相似文献/References:

[1]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[2]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(11):0.
[3]梁春燕,黄艳萍,刘志玲,等.子宫动脉栓塞术联合局部化疗对剖宫产瘢痕妊娠的临床疗效研究[J].中国计划生育和妇产科,2015,(05):0.
　LIANG Chun-yan,HUANG Yan-ping,LIU Zhi-ling,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(11):0.
[4]王聪,薛艳,田泉,等.绒毛膜癌脑转移4例分析[J].中国计划生育和妇产科,2015,(11):0.
　WANG Cong,XUE Yan,TIAN Quan,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2015,(11):0.
[5]迟聪,江小霞,黎清,等.子宫内膜小细胞癌合并糖尿病术后化疗致双眼失明1例[J].中国计划生育和妇产科,2016,(02):0.
[6]秦迎春.营养干预在宫颈癌患者同步放化疗中的作用分析[J].中国计划生育和妇产科,2016,(10):0.
　QIN Ying-chun,[J].Chinese Journal of Family Planning & Gynecotokology,2016,(11):0.
[7]李慧,汤小晗,卢美松*.肝素结合表皮生长因子与卵巢癌顺铂化疗耐药性关系的研究[J].中国计划生育和妇产科,2016,(12):15.
　LI Hui,TANG Xiao-han,LU Mei-song*.Study on relationship between HB-EGF and resistance of ovarian cancer to chemotherapy drug[J].Chinese Journal of Family Planning & Gynecotokology,2016,(11):15.
[8]何丽,林永红,李笑晓,等.防己诺林碱联用紫杉醇对耐药卵巢癌SKOV3/ADM细胞作用机制的初步研究[J].中国计划生育和妇产科,2017,(6):59.
　HE Li,LIN Yong-hong,LI Xiao-xiao,et al.Effect of fangchinoline combined with paclitaxel on drug resistant ovarian cancer SKOV3 / ADM cells: a preliminary study[J].Chinese Journal of Family Planning & Gynecotokology,2017,(11):59.
[9]卢丹华,洪莉*,杨将,等.Jagged1-STAT 3信号轴对卵巢癌细胞A 2780迁移能力的影响[J].中国计划生育和妇产科,2017,(8):72.
　LU Dan-hua,HONG Li*,YANG Jiang,et al.Effect of Jagged1-STAT 3 signal axis on migration ability of ovarian cancer cell A 2780[J].Chinese Journal of Family Planning & Gynecotokology,2017,(11):72.
[10]张雪梅.紫杉醇联合洛铂化疗方案对晚期初治卵巢癌术后 患者早期临床疗效及毒副反应发生率的分析[J].中国计划生育和妇产科,2018,(2):72.
　ZHANG Xue-mei.Early clinical efficacy and side effects of paclitaxel combined with lobaplatin regimen on postoperative patients with advanced ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(11):72.

更新日期/Last Update: 2018-11-25